Progress on clinical treatment of non-small cell lung cancer in elderly patients

doi:10.3877/cma.j.issn.2095-8757.2021.04.012

Abstract

Abstract:

Lung cancer is a solid tumor with high morbidity and mortality. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and elderly patients account for a high proportion of NSCLC patients. Treatment of NSCLC in elderly patients has always been a challenge in clinic. However, in recent years, the treatment of NSCLC has made rapid progress. Many new drugs and new therapies have provided effective clinical solutions for elderly patients. For elderly patients with early NSCLC, video-assisted thoracic surgery is a better choice than traditional open-chest surgery, which can achieve radical surgery and effectively reduce surgical complications and improve prognosis. For patients who do not have surgical indications, targeted and immunotherapy are new choices of preoperative/postoperative adjuvant therapy in addition to adjuvant chemotherapy, and even patients with advanced NSCLC have a variety of regimens such as targeted therapy, immunotherapy, chemotherapy, radiotherapy and combination therapy, so that the prognosis of elderly NSCLC patients can be effectively improved and individualized precision treatment can be realized. This article reviews the progress on the treatment of NSCLC in elderly patients, so as to provide reference for clinical treatment.

Key words: Non-small cell lung cancer, Aged, Surgical treatment, Neoadjuvant therapy, Chemotherapy, Radiotherapy, Targeted therapy, Immunotherapy

Rongxue Xing, Li Sun, Yingxuan Tian. Progress on clinical treatment of non-small cell lung cancer in elderly patients[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2021, 08(04): 48-53.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2021.04.012

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2021/V08/I04/48

References 43

[1]	曹毛毛，陈万青. GLOBOCAN 2020全球癌症统计数据解读[J/CD].中国医学前沿杂志（电子版），2021，13（3）：63-69.
[2]	Shi JF, Wang L, Wu N, et al. Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey[J]. Lung Cancer, 2019, 128:91-100.
[3]	British Thoracic Society and Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: Guidelines on the selection of patients with lung cancer for surgery[J]. Thorax, 2001, 56(2):89-108.
[4]	Port JL, Mirza FM, Lee PC, et al. Lobectomy in octogenarians with non-small cell lung cancer: Ramifications of increasing life expectancy and the benefits of minimally invasive surgery[J]. Ann Thorac Surg, 2011, 92(6):1951-1957.
[5]	Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008, 26(21):3552-3559.
[6]	NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data[J]. Lancet, 2014, 383(9928):1561-1571.
[7]	Houssaini MS, Damou M, Ismaili N. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting[J]. Cancer Treat Res Commun, 2020, 25:100239.
[8]	Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18):1711-1723.
[9]	Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med, 2018, 378(21):1976-1986.
[10]	Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(11):1413-1422.
[11]	Halmos B, Burke T, Kalyvas C, et al. A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs. nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS ≥1% metastatic NSCLC[J]. Cancers (Basel), 2020, 12(12):3648.
[12]	Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(11):1413-1422.
[13]	Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance[J]. Cell, 2008, 133(5):775-787.
[14]	陈思，赵泽锐，龙浩. 新辅助免疫治疗及联合化疗在NSCLC中的研究进展[J].中国肺癌杂志，2021，24（4）：284-292.
[15]	Fakiris AJ, Mcgarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study[J]. Int J Radiat Oncol Biol Phys, 2009, 75(3):677-682.
[16]	Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA, 2010, 303(11):1070-1076.
[17]	Senan S, Brade A, Wang LH, et al. PROCLAIM: Randomized phaseⅢ trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(9):953-962.
[18]	Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stageⅢA orⅢB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015, 16(2):187-199.
[19]	Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stageⅠ non-small-cell lung cancer: can SBRT be comparable to surgery[J]? Int J Radiat Oncol Biol Phys, 2011, 81(5):1352-1358.
[20]	Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: Stereotactic body radiotherapy of inoperable stageⅠ-Ⅱnon-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 73(4):1235-1242.
[21]	Shinde A, Li R, Kim J, et al. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly[J]. Semin Oncol, 2018, 45(4):210-219.
[22]	Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database[J]. J Clin Oncol, 2007, 25(35):5570-5577.
[23]	Mancini BR, Park HS, Harder EM, et al. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients[J]. Lung Cancer, 2016, 97:22-27.
[24]	任艳萍，焦玉新，戈伟强，等.立体定向放疗在高龄局限性肺癌患者中的疗效与安全性评估[J].老年医学与保健，2016，22（6）：387-390.
[25]	Veluswamy RR, Levy B, Wisnivesky JP. Chemotherapy in elderly patients with nonsmall cell lung cancer[J]. Curr Opin Pulm Med, 2016, 22(4):336-343.
[26]	Hinton S, Sandler A. Lung cancer in the elderly: Current and future chemotherapeutic options[J]. Drugs Aging, 2002, 19(5):365-375.
[27]	Langer CJ. Elderly patients with lung cancer: biases and evidence[J]. Curr Treat Options Oncol, 2002, 3(1):85-102.
[28]	Lilenbaum R. Management of advanced non-small-cell lung cancer in elderly populations[J]. Clin Lung Cancer, 2003, 5(3):169-173.
[29]	Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(4):620-627.
[30]	Karampeazis A, Vamvakas L, Kotsakis A, et al. Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phaseⅢstudy[J]. J Geriatr Oncol, 2017, 8(1):23-30.
[31]	Kudoh S, Takeda K, Nakagawa K, et al. PhaseⅢstudy of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)[J]. J Clin Oncol, 2006, 24(22):3657-3663.
[32]	Losanno T, Gridelli C. Recent advances in targeted advanced lung cancer therapy in the elderly[J]. Expert Rev Anticancer Ther, 2017, 17(9):787-797.
[33]	Ohashi K, Takamori M, Takahashi Y, et al. Efficacy and safety of gefitinib as first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC)[J]. Gan To Kagaku Ryoho, 2019, 46(1):55-59.
[34]	Roviello G, Zanotti L, Cappelletti MR, et al. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer[J]? Clin Exp Med, 2018, 18(1):15-20.
[35]	Furuta H, Uemura T, Yoshida T, et al. Efficacy and safety data of osimertinib in elderly patients with NSCLC who harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment[J]. Anticancer Res, 2018, 38(9):5231-5237.
[36]	Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer[J]. JAMA, 2012, 307(15):1593-1601.
[37]	Aggarwal C, Langer CJ. Systemic therapy for elderly patients with non-small cell lung cancer: Where do we stand in 2019?[J]. Cancer, 2020, 126(5):931-934.
[38]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135.
[39]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639.
[40]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550.
[41]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846.
[42]	Murray N, Turrisi AR. A review of first-line treatment for small-cell lung cancer[J]. J Thorac Oncol, 2006, 1(3):270-278.
[43]	Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: Current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066):299-311.

Please choose a citation manager

Content to export